On February 27, 2019, Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) announced that it closed its previously announced bought deal public offering of 23,000,000 units of the Company at a price of $0.25 per Unit for aggregate gross proceeds of $5,750,000. The team from WeirFoulds that represented Antibe in the deal included Robert Eberschlag, David Knight, Ryan Morris, Daniel Tessaro and Ann Lattanzio.
Each Unit was comprised of one common share of the Company and one-half of one common share purchase warrant. The net proceeds of the Offering will be used to fund research and development activities, including but not limited to, ATB-346’s clinical development, regulatory consulting fees, working capital needs and other general corporate purposes. Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.
WeirFoulds is proud to have assisted Antibe Therapeutics in the closing of this significant deal.
To learn more about our Corporate Law Practice Group or to contact one of our lawyers, visit our Corporate & Commercial overview page.
